Determination of Plasma Tissue Factor Antigen and Tissue Factor-Bearing Microparticles Activity in Healthy Subjects of Plasma Tissue Factor and Factor-Bearing

Background: Tissue factor (TF) is an integral membrane protein, normally separated from the blood by the vascular endothelium, which plays a key role in the initiation of blood coagulation. TF is present in plasma in various forms, including microparticles (MPs) and alternatively spliced TF. MPs are small (< 1 μm) membrane vesicles generated by activated or apoptotic cells. Levels of TF antigen (TF-Ag) and tissue factor-bearing microparticles (MP-TF) activity from different origins are thought to be associated with hypercoagulable states. The aim of the present study was to determine the reference range for plasma levels of TF-Ag and MP-TF activity in healthy subjects. Methods: To establish the reference range for plasma levels of TF-Ag and MP-TF activity and study the impact of sex and age we recruited 120 healthy subjects of Bulgarian nationality aged between 18 and 65. The selection criteria for the reference group were made to comply with the generally approved recommendations of the International Federation of Clinical Chemistry (IFCC). Clinical and routine hematological, biochemical and coagulation tests were performed to assess their health status. Plasma levels of TF-Ag were determined using ELISA and MP-TF activity by means of bio-immunoassay. Results: The reference range given as 95% of the measured values was defined for TF-Ag plasma levels with 59.2 pg/ml (90% CI: 50.9 -68.2) to 250.9 pg/ml (90% CI: 234.6-267.0) and for plasma levels of MP-TF activity with 0.03 pg/ml (90% CI: 0.01-0.06) to 0.47 pg/ml (90% CI: 0.43-0.50). We found no sex-related differences in plasma TF-Ag and MP-TF activity (p > 0.05), which obviates the need for separate reference intervals for men and women. Single-factor dispersion analysis found no age dependency of plasma levels for TF-Ag and MP-TF activity (p > 0.05) in the age range 18-65. Conclusion: The reference values for TF-Ag and MP-TF activity plasma levels calculated according to the type of distribution of results can be used as baseline criteria in clinical laboratory studies and for clinical purposes. clinical, instrumental (ECG, stress test) and laboratory evidence of coronary heart disease, hypertension, chronic obstructive pulmonary disease, bronchial asthma, peripheral vascular disease; chronic renal and liver diseases; systemic diseases of the connective tissues - lupus erythematodes, rheumatoid arthritis, collagenosis; acute inflammation or chronic inflammatory process in active treatment; neoplasma, prolonged use (during the last three months and during the time of study) of corticosteroids, hormonal drugs, psychotropic, narcotics; chronic use of alcohol and drug abuse.


Introduction
Tissue factor (TF) is a transmembrane glycoprotein that is essential for hemostasis. It binds the coagulation serine protease factor VII/VIIa (FVII/VIIa) to form a bimolecular complex that functions as the primary initiator of coagulation in vivo [1]. TF is expressed in the vascular adventitia, in astroglial cells, in organ capsules and is found in lungs and placenta at relatively high concentrations [2]. Unstimulated monocytes and endothelial cells do not express tissue factor but can be induced to express tissue factor on their surface under certain conditions, primarily by inflammatory cytokines and endotoxin [3][4][5]. Under normal circumstances cells in contact with blood do not express physiologically active TF. When mechanical or chemical damage of the vascular wall occurs, subendothelial TF is expressed/exposed to blood and binds plasma factor VIIa. The TF/factor VIIa complex initiates linked, enzymatic reactions that culminate in the generation [2]. Thrombin also activates platelets by cleavage of proteaseactivated receptors (PARs) [6]. TF is constitutively expressed at high levels in adventitial fibroblasts of the vessel wall and this facilitates the rapid activation of the coagulation cascade after injury [7,8].
Very low levels of TF are present in the blood of healthy individuals [9]. This so-called circulating TF is mostly present in the form of microparticles (MPs), which are submicron membrane vesicles (<1μm) derived from apoptotic and/or activated cells [10]. MPs have phospholipid surface which can assemble coagulation factors, resulting in procoagulant potential 2. The role of circulating TF in healthy individuals has not been defined [11]. Blood also contains soluble forms of TF, including alternatively spliced TF [11].
Many studies have shown that levels of TF and MP-TF activity are increased in various diseases, including cancer, sepsis, cardiovascular diseases and diabetes [12][13][14][15][16]. Prothrombotic tendency is characteristic of solid tumors. Cancer is associated with a four-fold increase in the risk for venous thromboembolism (VTE) and chemotherapy further increases this risk to between six and seven-fold compared with that in the general population [17].
Overall, the occurrence of VTE in patients with cancer is associated with increased morbidity and mortality [18]. Tissue factor (TF) has been considered a crucial role in the cancer VTE, especially the expression of TF on microparticles (MPs) which were released from tumor cells in the circulating blood [19,20]. TF expression has been reported in a number of cancers, such as prostate cancer, pancreatic cancer, ovarian cancer, non-smallcell lung cancer, colorectal cancer, renal cell cancer, hepatocellular cancer, glioma and breast cancer [21][22][23][24]. Treatment of patients with chemotherapeutic agents and/or radiation may additionally lead to an increase in the levels of MP-TF activity [19]. Monocytes are the major source of intravascular TF and are responsible for activation of coagulation during endotoxemia and sepsis [25].
Many studies have shown increased plasma levels of TF and MP-TF activity in cardiovascular diseases. Tissue factor plasma antigen is elevated in hypertensive patients and can be lowered by different classes of antihypertensive drugs [26]. It is observed that angiotensin II induces TF expression in monocytes, endothelial cells, and vascular smooth muscle cells [27]. On the other hand TF-MPs are released from atherosclerotic plaques, which leads to elevated TF plasma levels in patients with unstable angina and acute coronary syndromes [28]. It is also found that TF levels are elevated in diabetic patients13. The aim of the present study was to determine the reference range for plasma levels of TF-Ag and MP-TF activity in contingent of Bulgarian people. We recruited 120 healthy subjects of Bulgarian nationality for a period of 1 year to establish the reference range for plasma levels of TF-Ag and MP-TF activity and study the impact of sex and age.

Results
There were no statistically significant differences in the plasma levels of TF-Ag and MP-TF activity between males and females, which obviates the need for separate reference intervals for men and women Table 1. The distribution of the results for plasma levels of TF-Ag and MP-TF activity according to Kolmogorov -Smirnov test was Gaussian (p > 0.05) (Figures 2a & 2b). The results of the statistical analysis of the data for plasma levels of TF-Ag and MP-TF activity are shown in Table 2. The reference limits with their 90% confidence interval were determined using parametric analysis. It is obvious that x̄ and Me are similar, which is due to the regular      x̄ -mean, SD -standard deviation, SEM -standard error of mean x̄ -mean, SD -standard deviation, 90% CI -90% confidence interval, Me-median In spite of the fact that establishing reference values is an expensive and time -consuming task, it is recommended that they be determined in case of newly introduced parameters or parameters having genetic heterogeneity [29]. This is a reason for building reference intervals for a specific population from a specific region and with a specific structure. to evaluate the risk of appearance of incidents of thrombosis.

Conclusion
The reference values for plasma levels of TF-Ag and MP-TF activity are calculated according to the type of result distribution; they can be used as baseline criteria for clinical laboratory purposes.
The changes in the concentration of analyzed parameters for the age range 18-65 are not statistically significant, which means that it is not necessary to establish reference intervals for smaller age range within this group. The unavailability of sex-related differences in plasma levels of TF-Ag and MP-TF activity does not require separate reference intervals for men and women. The graphical model of reference interval provides immediate information about the type of distribution, the width and reliability of the reference values and makes it possible to easily visualize.